Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases

Annals of Surgical Oncology

Volumn 17, Issue 11, 2010, Pages 3000-3007

  Rossi, Carlo Riccardo ^a,b   Pasquali, Sandro ^a   Mocellin, Simone ^a   Vecchiato, Antonella ^b   Campana, Luca Giovanni ^a,b   Pilati, Pierluigi ^a   Zanon, Antonio ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; IN-TRANSIT METASTASIS; LIMB PERFUSION; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049469732     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1104-2     Document Type: Article

References (32)

1. Coit D, Ferrone C. Recurrent regional metastases of melanoma. In: Balch C, Houghton A, Sober A, Soong S, Atkins M, Thompson J, editors. Cutaneous melanoma. St. Louis, MO: I Quality Medical Publishing; 2009. p. 487-98.
2. LG Campana S Mocellin M Basso O Puccetti GL De Salvo V Chiarion-Sileni, et al. 2009 Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients Ann Surg Oncol 16 191 199 10.1245/s10434-008-0204-8 18987914
3. Alexander H, Fraker D, Eggermont A. Hypertermic regional perfusion for melanoma of the limbs. In: Balch C, Houghton A, Sober A, Soong S, Atkins M, Thompson J, editors. Cutaneous melanoma. St. Louis, MO: I Quality Medical Publishing; 2009. p. 519-40.
4. MB Lens M Dawes 2003 Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials Lancet Oncol 4 359 364 1:CAS:528: DC%2BD3sXkt1OksLo%3D 10.1016/S1470-2045(03)01117-3 12788409 (Pubitemid 36748424)
5. BC Vrouenraets OE Nieweg BB Kroon 1996 Thirty-five years of isolated limb perfusion for melanoma: indications and results Br J Surg 83 1319 1328 1:STN:280:DyaK2s%2FpvFyktA%3D%3D 10.1002/bjs.1800831004 8944445 (Pubitemid 26342147)
6. FJ Lejeune C Ruegg 2006 Recombinant human tumor necrosis factor: an efficient agent for cancer treatment Bull Cancer 93 E90 E100 1:STN:280:DC%2BD28rhtVansw%3D%3D 16935777
7. L Bertazza S Mocellin 2008 Tumor necrosis factor (TNF) biology and cell death Front Biosci 13 2736 2743 1:CAS:528:DC%2BD1cXhs1Cns7Y%3D 10.2741/2881 17981749 (Pubitemid 351611605)
8. JH de Wilt TL ten Hagen G de Boeck ST van Tiel EA de Bruijn AM Eggermont 2000 Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer 82 1000 1003 10.1054/bjoc.1999.1032 10737379
9. D Fraker H Alexander M Ross 2002 A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor plus interferon Ann Surg Oncol 9 S8 10.1007/BF02640542
10. DJ Grunhagen F Brunstein WJ Graveland AN van Geel JH de Wilt AM Eggermont 2004 One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases Ann Surg 240 939 947 10.1097/01.sla.0000146147.89667.ed 15570199 discussion 47-8 (Pubitemid 39602121)
11. EM Noorda BC Vrouenraets OE Nieweg BN van Geel AM Eggermont BB Kroon 2004 Isolated limb perfusion for unresectable melanoma of the extremities Arch Surg 139 1237 1242 10.1001/archsurg.139.11.1237 15545572 (Pubitemid 39463461)
12. CR Rossi M Foletto S Mocellin P Pilati M Lise 2004 Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases Ann Surg Oncol 11 173 177 10.1245/ASO.2004.03. 019 14761920 (Pubitemid 40486792)
13. F Di Filippo CR Rossi M Santinami F Cavaliere R Garinei M Anza, et al. 2006 Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis In Vivo 20 739 742 1:CAS:528:DC%2BD2sXitleqs70%3D 17203758
14. BC Vrouenraets GA Hart AM Eggermont JM Klaase BN van Geel OE Nieweg, et al. 1999 Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma J Am Coll Surg 188 522 530 1:STN:280:DyaK1M3kvFKlsg%3D%3D 10.1016/S1072-7515(99)00018-6 10235581 (Pubitemid 29214366)
15. BC Vrouenraets AM Eggermont AA Hart JM Klaase AN van Geel OE Nieweg, et al. 2001 Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone Eur J Surg Oncol 27 390 395 1:STN:280:DC%2BD3MzlslGrsQ%3D%3D 10.1053/ejso.2001.1124 11417986 (Pubitemid 32624542)
16. A Sanki PC Kam JF Thompson 2007 Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology Ann Surg 245 591 596 10.1097/01.sla.0000251746.02764.fc 17414608 (Pubitemid 46555663)
17. D Lienard AM Eggermont HS Koops B Kroon G Towse S Hiemstra, et al. 1999 Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study Melanoma Res 9 491 502 1:CAS:528:DyaK1MXntlaktbo%3D 10.1097/00008390-199910000-00009 10596916
18. TG Zogakis DL Bartlett SK Libutti DJ Liewehr SM Steinberg DL Fraker, et al. 2001 Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma Ann Surg Oncol 8 771 778 1:STN:280:DC%2BD38%2FkvVynsg%3D%3D 10.1007/s10434-001-0771-4 11776490
19. HR Alexander Jr DL Fraker DL Bartlett SK Libutti SM Steinberg P Soriano, et al. 2010 Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters J Clin Oncol 28 114 118 10.1200/JCO.2009.23.7511 19901107
20. WR Cornett LM McCall RP Petersen MI Ross HA Briele RD Noyes, et al. 2006 Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol 24 4196 4201 1:CAS:528:DC%2BD28XhtVantbvL 10.1200/JCO.2005.05.5152 16943537 (Pubitemid 46622299)
21. Lejeune FJ, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol. 2007;25:1449-50 (author reply 50-1).
22. CR Rossi M Foletto P Pilati S Mocellin M Lise 2002 Isolated limb perfusion in locally advanced cutaneous melanoma Semin Oncol 29 400 409 10.1053/sonc.2002.34119 12170443 (Pubitemid 34857888)
23. D Casara D Rubello PL Pilati R Scalerta M Foletto CR Rossi 2002 A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion Tumori 88 S61 S63 1:STN:280:DC%2BD38nht1Sjuw%3D%3D 12369560
24. J Wieberdink C Benckhuysen RP Braat EA van Slooten GA Olthuis 1982 Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol 18 905 910 1:STN:280:DyaL3s7jtFOksQ%3D%3D 10.1016/0277-5379(82)90235-8 6891640
25. DJ Grunhagen JH de Wilt AN van Geel WJ Graveland C Verhoef AM Eggermont 2005 TNF dose reduction in isolated limb perfusion Eur J Surg Oncol 31 1011 1019 1:STN:280:DC%2BD2Mrpt1OmsQ%3D%3D 10.1016/j.ejso.2005.07.003 16099618 (Pubitemid 41671116)
26. DL Fraker HR Alexander M Andrich SA Rosenberg 1996 Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study J Clin Oncol 14 479 489 1:CAS:528:DyaK28XhsV2lsbg%3D 8636761
27. F Di Filippo P Giacomini CR Rossi M Santinami M Anza R Garinei, et al. 2009 Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion In Vivo 23 347 352 1:CAS:528:DC%2BD1MXltFyis74%3D 19414425
28. MG Rosenblum NJ Donato JU Gutterman 1988 Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture Lymphokine Res 7 107 117 1:CAS:528:DyaL1cXkslWktLY%3D 2457138
29. CR Rossi S Mocellin P Pilati M Foletto L Campana L Quintieri, et al. 2005 Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas Ann Surg Oncol 12 398 405 10.1245/ASO.2005.12.038 15915374 (Pubitemid 40880675)
30. Noorda EM, Takkenberg B, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, et al. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol. 2004;11:-491-9.
31. MK Parmar V Torri L Stewart 1998 Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 2815 2834 1:STN:280:DyaK1M7itVWksA%3D%3D 10.1002/(SICI)1097-0258(19981230)17: 24<2815::AID-SIM110>3.0.CO;2-8 9921604 (Pubitemid 28562978)
32. CR Rossi F Russano S Mocellin V Chiarion-Sileni M Foletto P Pilati, et al. 2008 TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial Ann Surg Oncol 15 1218 1223 10.1245/s10434-007-9791-z 18247095